Lamivudine/raltegravir

Lamivudine/raltegravir, sold under the brand name Dutrebis, is a combination medication of lamivudine and raltegravir which is used in the treatment of HIV/AIDS.[1] It is taken by mouth.[1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes.[1] It was approved for medical use in the United States in 2015.[1]

Lamivudine/raltegravir
Combination of
LamivudineReverse-transcriptase inhibitor
RaltegravirIntegrase inhibitor
Clinical data
Trade namesDutrebis
Routes of
administration
Oral
Legal status
Legal status
Identifiers
KEGG

References

  1. "Dutrebis (lamivudine and raltegravir)" (PDF). FDA. Retrieved 10 December 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.